<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare effects of different oral <z:chebi fb="0" ids="35526">hypoglycemic drugs</z:chebi> as first-line therapy on <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> subfractions in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Sixty overweight type 2 diabetic patients not on <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy were randomized to <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, or <z:chebi fb="0" ids="31654">gliclazide</z:chebi> after a 3-month dietary run-in </plain></SENT>
<SENT sid="2" pm="."><plain>Drug doses were uptitrated for 3 months to optimize glycemia and were kept fixed for a further 3 months </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi> subfractions (<z:chebi fb="15" ids="39026">LDL</z:chebi>(1), <z:chebi fb="15" ids="39026">LDL</z:chebi>(2), and <z:chebi fb="15" ids="39026">LDL</z:chebi>(3)) were prepared by density gradient ultracentrifugation at randomization and study end </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="4" ids="17855">Triglycerides</z:chebi>, cholesterol, total protein, and <z:chebi fb="1" ids="16247">phospholipids</z:chebi> were measured and mass of subfractions calculated </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> subfractions were prepared by precipitation </plain></SENT>
<SENT sid="6" pm="."><plain>The primary end point was change in proportion of <z:chebi fb="15" ids="39026">LDL</z:chebi> as <z:chebi fb="15" ids="39026">LDL</z:chebi>(3) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: HbA(1c), <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, <z:chebi fb="105" ids="17234">glucose</z:chebi>, and cholesterol were comparable across groups at baseline and over time </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi>(3) mass and the <z:chebi fb="15" ids="39026">LDL</z:chebi>(3)-to-<z:chebi fb="15" ids="39026">LDL</z:chebi> ratio fell with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>(3) mass 36.2 to 28.0 mg/dl, P &lt; 0.01; <z:chebi fb="15" ids="39026">LDL</z:chebi>(3)-to-<z:chebi fb="15" ids="39026">LDL</z:chebi> 19.2:13.3%, P &lt; 0.01) and <z:chebi fb="0" ids="6801">metformin</z:chebi> (42.7 to 31.5 mg/dl, P &lt; 0.01; 21.3:16.2%, P &lt; 0.01, respectively) with no change on <z:chebi fb="0" ids="31654">gliclazide</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi>(3) reductions were associated with reciprocal <z:chebi fb="15" ids="39026">LDL</z:chebi>(1) increases </plain></SENT>
<SENT sid="10" pm="."><plain>Changes were independent of BMI, glycemic control, and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Total <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> increased on <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (1.28 to 1.36 mmol/l, P = 0.02) but not <z:chebi fb="0" ids="31654">gliclazide</z:chebi> (1.39 to 1.37 mmol/l, P = NS) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (1.26 to 1.18 mmol/l, P = NS), largely due to an <z:chebi fb="17" ids="39025">HDL</z:chebi>(2) increase (0.3 to 0.4 mmol/l, P &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi>(3) cholesterol fell on <z:chebi fb="0" ids="6801">metformin</z:chebi> (0.9 to 0.85 mmol/l, P &lt; 0.01) </plain></SENT>
<SENT sid="13" pm="."><plain>On <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi>, the <z:chebi fb="17" ids="39025">HDL</z:chebi>(2)-to-<z:chebi fb="17" ids="39025">HDL</z:chebi>(3) ratio increased compared with no change on <z:chebi fb="0" ids="31654">gliclazide</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: For the same improvement in glycemic control, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> produce favorable changes in <z:chebi fb="17" ids="39025">HDL</z:chebi> and <z:chebi fb="15" ids="39026">LDL</z:chebi> subfractions compared with <z:chebi fb="0" ids="31654">gliclazide</z:chebi> in overweight type 2 diabetic patients </plain></SENT>
<SENT sid="15" pm="."><plain>Such changes may be associated with reduced <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> risk and may inform the choice of initial oral <z:chebi fb="0" ids="35526">hypoglycemic agent</z:chebi> </plain></SENT>
</text></document>